SPR 741

Drug Profile

SPR 741

Alternative Names: SPR 741

Latest Information Update: 01 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Northern Antibiotics
  • Developer Evotec AG; Spero Therapeutics
  • Class Antibacterials; Peptides; Polymixins
  • Mechanism of Action Bacterial outer membrane protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Gram-negative infections

Most Recent Events

  • 02 May 2017 Spero Therapeutics plans a clinical trial for Gram-negative infections (Combination therapy with SPR 720) in 2017
  • 18 Apr 2017 Adverse events, pharmacokinetics and antimicrobial activity data from preclinical studies in Gram-negative infections presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2017)
  • 18 Apr 2017 Antimicrobial data from a preclinical study in Gram-negative infections released by Spero Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top